Back Back
Mpox Vaccination for Vulnerable Populations

CE / CME

Protection Beyond Outbreaks: Routine Mpox Vaccination for Vulnerable Populations

Nurses: 1.00 Nursing contact hour

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit™

Released: July 17, 2024

Expiration: July 16, 2025

CME/CE Information

Activity

Progress
1 2
Course Completed

How Effective Is the Mpox Vaccine for PEP?

Aniruddha Hazra, MD:
Another role for the mpox vaccine that was of particular interest early in the current outbreak when it was too late for those infected to be vaccinated for prevention, is PEP. Let’s discuss efficacy and optimal timing of this strategy.

Mpox Vaccination: PEP

Carlos del Rio, MD, FIDSA:
Yes, PEP using the mpox vaccine is an important approach that we have been able to use in the current outbreak. For anyone who has been exposed to the virus, has not yet been vaccinated, and presents for PEP, it also provides an opportunity to vaccinate.

Download

Mpox Vaccination: PEP Timing

Aniruddha Hazra, MD:
With regard to the timing of PEP, the general rule that applies with any PEP strategy is: the earlier the better. For mpox, the recommendation is as soon as possible, and ideally within 4 days of the exposure. There may still be some protection if the vaccine is given from days 4 to 14 following the exposure, but beyond 2 weeks after exposure, the benefit is not really known.

Carlos del Rio, MD, FIDSA:
I agree, but even someone presenting at that late time frame for PEP can still benefit from receiving the full 2-dose series of the vaccine for future protection. The exposure demonstrates risk and provides an opportunity to vaccinate.

Download

If following ACIP recommendations, the mpox vaccine should be used for:

NYC Real-World Effectiveness of PEP Against Mpox

Aniruddha Hazra, MD:

Real-world data from New York City on the use of MVA-BN as PEP showed that even when it was delayed, given 15 to 21 days after exposure, there was still some effectiveness, likely in part from the vaccine conferring protection from future mpox exposures.

 

Carlos del Rio, MD, FIDSA:
I absolutely think that is the case. There is still a significant number of people who would benefit from mpox vaccination, and we should do what we can to make sure they get vaccinated.

Download
BACK | NEXT